Amit B. Agarwal

586 total citations
10 papers, 429 citations indexed

About

Amit B. Agarwal is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Amit B. Agarwal has authored 10 papers receiving a total of 429 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 5 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Amit B. Agarwal's work include Multiple Myeloma Research and Treatments (6 papers), Protein Degradation and Inhibitors (3 papers) and Cancer Mechanisms and Therapy (2 papers). Amit B. Agarwal is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), Protein Degradation and Inhibitors (3 papers) and Cancer Mechanisms and Therapy (2 papers). Amit B. Agarwal collaborates with scholars based in United States, Australia and France. Amit B. Agarwal's co-authors include Joel Johansson, Asher Chanan‐Khan, Cyrille Touzeau, Jeremy A. Ross, Shaji Kumar, Maria Verdugo, Philippe Moreau, Wijith Munasinghe, Andrew W. Roberts and Thierry Façon and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Critical Reviews in Oncology/Hematology.

In The Last Decade

Amit B. Agarwal

9 papers receiving 427 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amit B. Agarwal United States 6 238 203 203 123 100 10 429
E. Jane Leonard United States 10 166 0.7× 206 1.0× 56 0.3× 77 0.6× 116 1.2× 24 415
Hisao Nagoshi Japan 12 299 1.3× 136 0.7× 149 0.7× 54 0.4× 118 1.2× 38 520
Jessica Haug United States 10 303 1.3× 141 0.7× 244 1.2× 57 0.5× 57 0.6× 23 423
Santiago Barrio Spain 13 359 1.5× 169 0.8× 320 1.6× 89 0.7× 84 0.8× 37 521
J Ackermann Austria 12 280 1.2× 185 0.9× 287 1.4× 87 0.7× 85 0.8× 17 445
Ying-Ming Jou United States 6 353 1.5× 439 2.2× 349 1.7× 77 0.6× 44 0.4× 8 631
Koorosh Korfi United Kingdom 8 228 1.0× 148 0.7× 241 1.2× 151 1.2× 85 0.8× 18 549
Zohar Sachs United States 12 246 1.0× 83 0.4× 138 0.7× 53 0.4× 42 0.4× 36 383
Claudia E. Paba‐Prada United States 12 462 1.9× 305 1.5× 470 2.3× 146 1.2× 100 1.0× 27 658
Greg Ahmann United States 9 435 1.8× 179 0.9× 410 2.0× 35 0.3× 56 0.6× 18 541

Countries citing papers authored by Amit B. Agarwal

Since Specialization
Citations

This map shows the geographic impact of Amit B. Agarwal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amit B. Agarwal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amit B. Agarwal more than expected).

Fields of papers citing papers by Amit B. Agarwal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amit B. Agarwal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amit B. Agarwal. The network helps show where Amit B. Agarwal may publish in the future.

Co-authorship network of co-authors of Amit B. Agarwal

This figure shows the co-authorship network connecting the top 25 collaborators of Amit B. Agarwal. A scholar is included among the top collaborators of Amit B. Agarwal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amit B. Agarwal. Amit B. Agarwal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Jagannath, Sundar, Yi Lin, Hartmut Goldschmidt, et al.. (2020). KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa.. Journal of Clinical Oncology. 38(15_suppl). 8525–8525. 13 indexed citations
2.
Moreau, Philippe, Asher Chanan‐Khan, Andrew W. Roberts, et al.. (2017). A Phase 1b Study of Venetoclax Combined with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 17(1). e16–e16.
3.
4.
Moreau, Philippe, Asher Chanan‐Khan, Andrew W. Roberts, et al.. (2017). Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 130(22). 2392–2400. 205 indexed citations
5.
Xie, Jipan, Kejal Parikh, Christina Chen, et al.. (2017). Impact of FDA approval of lenalidomide maintenance therapy in the first-line treatment of multiple myeloma after autologous stem cell transplant on total healthcare costs.. Journal of Clinical Oncology. 35(15_suppl). e19509–e19509. 2 indexed citations
6.
Agarwal, Amit B. & Ali McBride. (2016). Understanding the biosimilar approval and extrapolation process—A case study of an epoetin biosimilar. Critical Reviews in Oncology/Hematology. 104. 98–107. 8 indexed citations
7.
Moreau, Philippe, Asher Chanan‐Khan, Andrew W. Roberts, et al.. (2016). Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma. Blood. 128(22). 975–975. 18 indexed citations
8.
Moreau, Philippe, Asher Chanan‐Khan, Andrew W. Roberts, et al.. (2015). Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results. Blood. 126(23). 3038–3038. 19 indexed citations
9.
Singh, Parminder, et al.. (2014). Epidemiology and outcome of sarcomatoid renal cell cancer compared to clear cell renal cancer: A Surveillance, Epidemiology, and End Results (SEER) database review.. Journal of Clinical Oncology. 32(4_suppl). 504–504. 1 indexed citations
10.
Friedberg, Jonathan W., Daruka Mahadevan, Daniel O. Persky, et al.. (2013). Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas. Journal of Clinical Oncology. 32(1). 44–50. 161 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. Jane Leonard Breakdown of academic impact, for papers by Hisao Nagoshi Breakdown of academic impact, for papers by Jessica Haug Breakdown of academic impact, for papers by Santiago Barrio Breakdown of academic impact, for papers by J Ackermann Breakdown of academic impact, for papers by Ying-Ming Jou Breakdown of academic impact, for papers by Koorosh Korfi Breakdown of academic impact, for papers by Zohar Sachs Breakdown of academic impact, for papers by Claudia E. Paba‐Prada Breakdown of academic impact, for papers by Greg Ahmann
Rankless by CCL
2026